Lupus nephritis: a critical review - PubMed (original) (raw)
Review
Lupus nephritis: a critical review
Andrea T Borchers et al. Autoimmun Rev. 2012 Dec.
Abstract
Lupus nephritis remains one of the most severe manifestations of systemic lupus erythematosus associated with considerable morbidity and mortality. A better understanding of the pathogenesis of lupus nephritis is an important step in identifying more targeted and less toxic therapeutic approaches. Substantial research has helped define the pathogenetic mechanisms of renal manifestations and, in particular, the complex role of type I interferons is increasingly recognized; new insights have been gained into the contribution of immune complexes containing endogenous RNA and DNA in triggering the production of type I interferons by dendritic cells via activation of endosomal toll-like receptors. At the same time, there have been considerable advances in the treatment of lupus nephritis. Corticosteroids have long been the cornerstone of therapy, and the addition of cyclophosphamide has contributed to renal function preservation in patients with severe proliferative glomerulonephritis, though at the cost of serious adverse events. More recently, in an effort to minimize drug toxicity and achieve equal effectiveness, other immunosuppressive agents, including mycophenolate mofetil, have been introduced. Herein, we provide a detailed review of the trials that established the equivalency of these agents in the induction and/or maintenance therapy of lupus nephritis, culminating in the recent publication of new treatment guidelines by the American College of Rheumatology. Although newer biologics have been approved and continue to be a focus of research, they have, for the most part, been relatively disappointing compared to the effectiveness of biologics in other autoimmune diseases. Early diagnosis and treatment are essential for renal preservation.
Copyright © 2012 Elsevier B.V. All rights reserved.
Similar articles
- [Lupus nephritis].
Morović-Vergles J, Salamon L. Morović-Vergles J, et al. Reumatizam. 2009;56(2):34-40. Reumatizam. 2009. PMID: 20429260 Review. Croatian. - Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions.
Ortega LM, Schultz DR, Lenz O, Pardo V, Contreras GN. Ortega LM, et al. Lupus. 2010 Apr;19(5):557-74. doi: 10.1177/0961203309358187. Epub 2010 Jan 20. Lupus. 2010. PMID: 20089610 Review. - Lupus nephritis: is the kidney biopsy currently necessary in the management of lupus nephritis?
Giannico G, Fogo AB. Giannico G, et al. Clin J Am Soc Nephrol. 2013 Jan;8(1):138-45. doi: 10.2215/CJN.03400412. Epub 2012 Sep 13. Clin J Am Soc Nephrol. 2013. PMID: 22977215 Review. - Treatment of lupus nephritis.
Dolff S, Berden JH, Bijl M. Dolff S, et al. Expert Rev Clin Immunol. 2010 Nov;6(6):901-11. doi: 10.1586/eci.10.79. Expert Rev Clin Immunol. 2010. PMID: 20979555 Review. - Lupus nephritis.
Agrawal N, Chiang LK, Rifkin IR. Agrawal N, et al. Semin Nephrol. 2006 Mar;26(2):95-104. doi: 10.1016/j.semnephrol.2005.09.002. Semin Nephrol. 2006. PMID: 16530602 Review.
Cited by
- A systems approach to renal inflammation in SLE.
Berthier CC, Kretzler M, Davidson A. Berthier CC, et al. Clin Immunol. 2017 Dec;185:109-118. doi: 10.1016/j.clim.2016.08.015. Epub 2016 Aug 14. Clin Immunol. 2017. PMID: 27534926 Free PMC article. Review. - Whole-genome transcription and DNA methylation analysis of peripheral blood mononuclear cells identified aberrant gene regulation pathways in systemic lupus erythematosus.
Zhu H, Mi W, Luo H, Chen T, Liu S, Raman I, Zuo X, Li QZ. Zhu H, et al. Arthritis Res Ther. 2016 Jul 13;18:162. doi: 10.1186/s13075-016-1050-x. Arthritis Res Ther. 2016. PMID: 27412348 Free PMC article. - Immunoregulatory role of AC007278.3 and HOTAIR long non-coding RNAs in lupus nephritis: potential biomarkers and therapeutic targets.
Rasuli E, Javidi-Aghdam K, Akbarzadeh-Khiavi M, Abdshah A, Gadakchi L, Jafarpour M, Khabbazi A, Farajnia S, Safary A, Shaykh-Baygloo N. Rasuli E, et al. Mol Biol Rep. 2024 Oct 19;51(1):1075. doi: 10.1007/s11033-024-10019-4. Mol Biol Rep. 2024. PMID: 39425850 - Facilitated expansion of Th17 cells in lupus nephritis patients.
Jakiela B, Kosałka J, Plutecka H, Bazan-Socha S, Sanak M, Musiał J. Jakiela B, et al. Clin Exp Immunol. 2018 Dec;194(3):283-294. doi: 10.1111/cei.13196. Epub 2018 Sep 23. Clin Exp Immunol. 2018. PMID: 30086206 Free PMC article. - Metabolomics approach reveals urine biomarkers and pathways associated with the pathogenesis of lupus nephritis.
Kalantari S, Chashmniam S, Nafar M, Zakeri Z, Parvin M. Kalantari S, et al. Iran J Basic Med Sci. 2019 Nov;22(11):1288-1295. doi: 10.22038/ijbms.2019.38713.9178. Iran J Basic Med Sci. 2019. PMID: 32128093 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources